Tag: Biosense Webster

First patient treated in STELLAR US study evaluating next-generation balloon ablation...

Biosense Webster has enrolled and treated the first patient in its STELLAR US investigational device exemption (IDE) study. The study will evaluate the safety...

New report on the burden of AF in Europe released

During AF Association Global AF Aware Week, Biosense Webster EMEA has published a report that uncovers the growing burden of atrial fibrillation (AF) on...

Biosense Webster announces first patients enrolled in post-market approval study for...

Johnson & Johnson have announced that Biosense Webster has received approval from the US Food and Drug Administration (FDA) for its VISITAG SURPOINT External...

New data demonstrates >90% year 1 success rate for radiofrequency ablation...

Biosense Webster, a Division of Johnson & Johnson Medical NV/SA, and a leader in the diagnosis and treatment of cardiac arrhythmias, recently presented new...

Biosense Webster launches Carto 3 system Carto Visitag module with Ablation...

Biosense Webster has launched of the Carto Visitag module with Ablation Index, a new technology providing visual indication based on the integration of power,...

Biosense Webster announces US launch of ThermoCool SmartTouch SF catheter

Biosense Webster has announced the US launch of the ThermoCool SmartTouch SF catheter. According to a company release, the catheter pairs contact force technology...